Saudi Arabia’s Fight Against Lung Cancer: Progress and Challenges

Lung cancer is one of the deadliest malignancies, claiming 1.5 million lives worldwide annually. It is the fifth most common cancer among men in Saudi Arabia and the seventh most common overall. Lung cancer screening, early diagnosis, and precise treatment can save lives. This article explores how we can provide lung cancer patients and the general public with comprehensive support to ensure access to the best treatment and quality of life.

Lung Cancer Screening

Diagnosing lung cancer in the initial stages is indisputably valuable. Survival rates change from 85 percent in stage 1 to an abysmal 1 percent in stage 4. Computed tomography (CT) scan using lower doses of radiation (called low-dose CT) is the strategy of choice for lung cancer screening. Sputum testing and X-rays are ineffective for early detection of lung cancer. 

Healthcare providers may need bronchoscopy and biopsy to confirm a lung cancer diagnosis and differentiate the type. Positron emission tomography (PET) helps you judge the spread and stage of lung cancer. In addition, an endobronchial ultrasound scan (EBUS) will let you take a biopsy from the mediastinal lymph nodes. You could also consider thoracoscopy or mediastinoscopy, though these procedures require general anesthesia.

Screening Strategy

An effective screening program can reduce lung cancer mortality by 20 percent. Mass screening is not recommended in Saudi Arabia, but targeted screening holds promise. You can consider offering lung cancer screening to the following high-risk populations:

  • Individuals aged 50 to 74 years
  • Current smokers or those who quit in the last 15 years
  • Those who have smoked 30 pack-years (one pack a day for 30 years or two packs a day for 15 years)

It’s also recommended to evaluate people with symptoms suggestive of lung cancer, such as:

  • Breathing difficulties
  • Hemoptysis or coughing up blood
  • Chest pain
  • Fatigue
  • Unintentional weight loss
  • Frequent pneumonia

These symptoms often signify late-stage lung cancer. Diagnosis after symptoms appear has a poor prognosis.

It is also crucial to raise the public’s lung cancer awareness. Healthcare providers should screen patients for smoking and provide counselling. You can refer smokers to a smoking cessation program if necessary.

Any screening program for lung cancer should include help for smoking cessation. This will reduce the likelihood of cancer in people who stop. If you detect lung cancer, smoking cessation is even more important. Cancer treatments are less effective in people who continue to smoke, and they also have a higher risk of complications and death.

Smoking is growing in popularity in Saudi Arabia — about 28.9 percent of Saudi men smoke and are at risk for lung cancer. You can prevent lung cancer suffering and mortality by providing counselling and lung cancer screening. 

Stay Current With MDBriefCase

Help improve lung cancer care. Access free accredited courses on MDBriefCase designed to keep you up-to-date on the current landscape of lung cancer and optimal treatment approaches: 

Lung Cancer: Risk Factors, Newly Approved Therapies and the Role of the Pharmacist in Lung Cancer Therapy

Enhancing Oncology Care for Breast and Lung Cancer Patients in the Kingdom of Saudi Arabia

Author Agreement

In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Academy website (the “Website”), you (“You”) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Academy website.

Audience and Appropriate Topics

The  Healthcare Leadership Academy welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.


Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Academy may run between 500 and 1000 words. 


MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement